4Search

FairPowerfulClutter-Free
Your New Search Engine


Biospace.com

favicon biospace.com —  5+ hour, 58+ min ago

Oncolytic Virus Cancer Immunotherapy Market Companies Clinical Trials Insight 2028

biospace.com > article

.... - IMLYGIC, Oncorine, Delytact: Availability, Dosage and Price Analysis. - Oncolytic Virus Immunotherapy Clinical Pipeline By Country, Phase, Indication...

thumbnail favicon biospace.com —  4+ hour, 47+ min ago

Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis

biospace.com > article

...Amid rampant buyout speculation, Mirati Therapeutics reported that it will continue its final analysis of the Phase III SAPPHIRE trial following... ...Beyond the combination with Bristol Myers Squibb's Opdivo, Mirati has also paired the drug with BeiGene's checkpoint inhibitor, tislelizumab....

favicon biospace.com —  22+ hour, 5+ min ago

Alvotech Announces Changes to its Leadership Team

biospace.com > article > releases

...Operating Officer. - Mark Levick has decided to step down as Chief Executive Officer and Robert Wessman, Executive Chairman and founder, will become... ...Hafrun Fridriksdottir, previously Executive Vice President and Head of Global R&D at Teva, has been appointed Chief Operating Officer....

favicon biospace.com —  9+ hour, 49+ min ago

Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

biospace.com > article > releases

...of Social Anxiety Disorder (SAD) and data on the pharmacometrics analysis and drug reformulation of BNC210 for the treatment of PTSD at the 61st... ...for Evaluation as an Acute Treatment for Social Anxiety Disorder....

favicon biospace.com —  17+ hour, 22+ min ago

Enzolytics Recognizes World AIDS Day and Highlights the Company's Focus on Producing Effective Therapies for Treating HIV

biospace.com > article > releases

...Enzolytics Recognizes World AIDS Day and Highlights the Company's Focus on Producing Effective Therapies for Treating HIV.... ...Cabenuva by VIIV Healthcare costs $48K a year....

favicon biospace.com —  22+ hour, 5+ min ago

Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR® AnkleThe approval of the STAR PSI System

biospace.com > article

...Food and Drug Administration (FDA) has approved the STAR Patient Specific Instrumentation (STAR PSI System) for use with the Company's STAR® total... ...Gregory Lundeeni, a foot and ankle orthopedic surgeon based in Reno, Nevada....

favicon biospace.com —  5+ hour, 58+ min ago

Controlled Release Drug Delivery Market Clinical Trials Insight 2028

biospace.com > article

.... - Controlled Release Drug Clinical Pipeline Insight By Phase, Indication, Company, Country & Drug Class. - Comprehensive Clinical insight On More... ...Similarly, Bydureon and Tecfidera are extended release tablets used in diabetes and multiple sclerosis respectively....

favicon biospace.com —  5+ hour, 58+ min ago

Anti TIGIT Antibody Clinical Trials Market Opportunity Insight 2023

biospace.com > article

...conventional treatment methods which were often systematic and untargeted, hence showed adverse effects because of off-target interactions between the drugs... ...M6223 (Merck), IBI939 (Innovent) and AB154/domvanalimab (Arcus) are some TIGIT-inhibitors in clinical trials for patients suffering from various...

favicon biospace.com —  11+ hour, 26+ min ago

Bio-Thera Solutions Announces Presentation of BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Selection Summit

biospace.com > article > releases

...and a pipeline of biosimilars, today announced that Jin-Chen Yu, SVP, Research will present a talk on BAT8009 (B7-H3-ADC) at the 2nd Annual ADC... ...Bio-Thera Solutions, Ltd., a leading global biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics...

favicon biospace.com —  12+ hour, 7+ min ago

Qilu Pharmaceutical Releases Latest Results of QL1706 plus Chemotherapy +/- Bevacizumab for the Treatment of Non-Small Cell Lung Cancer in the Phase II Study at ESMO Asia Congress 2022

biospace.com > article > releases

...poster presentations (325P and 332P) at the European Society for Medical Oncology (ESMO) Asia Congress 2022.... ...Xiaoyan Kang, Head of Qilu Pharmaceutical clinical research center, stated, "We are pleased to release the latest study results of QL1706 plus chemotherapy...



**Content contained on this site is provided on an “as is” basis. 4Internet, LLC makes no commitments regarding the content and does not review it, so don't assume that it's been reviewed. What you see here may not be accurate and should not be relied upon. The content does not necessarily represent the views and opinions of 4Internet, LLC. You use this service and everything you see here at your own risk. Content displayed may be subject to copyright. Content is removed on a case by case basis. To request that content be removed, contact us using the following form: Contact Us.